Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAFV600 Mutation

@article{Dhillon2016DabrafenibPT,
  title={Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAFV600 Mutation},
  author={Sohita Dhillon},
  journal={Targeted Oncology},
  year={2016},
  volume={11},
  pages={417-428}
}
The BRAF inhibitor dabrafenib (Tafinlar®) and the MEK inhibitor trametinib (Mekinist®) are indicated, as monotherapy or in combination with each other, for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600 mutation. This article reviews the therapeutic efficacy and tolerability of combination treatment with dabrafenib and trametinib in this indication and summarizes relevant pharmacological data. Dabrafenib plus trametinib significantly prolonged progression… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 49 REFERENCES

Current and future roles of targeted therapy and immunotherapy in advanced melanoma.

  • Journal of managed care & specialty pharmacy
  • 2014
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2012
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Improved overall survival in melanoma with combined dabrafenib and trametinib.

  • The New England journal of medicine
  • 2015
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

  • The New England journal of medicine
  • 2014
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Combined BRAF andMEK inhibition inmelanomawith BRAFV600mutations

KT Flaherty, JR Infante, A Daud
  • N Engl JMed
  • 2012
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL